

CITATION REPORT

List of articles citing

Economic aspects of bladder cancer: what are the benefits and costs?

DOI: 10.1007/s00345-009-0395-z

World Journal of Urology, 2009, 27, 295-300.

Source: <https://exaly.com/paper-pdf/46257395/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
350	Combinations of urine-based tumour markers in bladder cancer surveillance. 2009 , 43, 461-6		43
349	Hexyl aminolevulinate fluorescence cystoscopy in bladder cancer. 2009 , 9, 1055-63		7
348	[Photodynamic diagnosis (PDD) in non-muscle invasive bladder cancer. Literature review]. 2009 , 33, 965-75		6
347	Emerging targeted therapies for bladder cancer: a disease waiting for a drug. 2009 , 28, 355-67		34
346	Invasive bladder cancer and the role of follow-up: should we consider the match over at radical cystectomy or should we play for extra time?. 2010 , 58, 495-7		2
345	Biomarkers in bladder cancer. 2010 , 105, 608-13		36
344	Editorial comment. 2010 , 183, 86; discussion 86		
343	Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. 2010 , 184, 1907-13		183
342	Photodynamic Diagnosis in NonMuscle-Invasive Bladder Cancer. 2010 , 9, 411-418		3
341	Imaging of urothelial cancers: what the urologist needs to know. 2011 , 196, 1249-54		13
340	Long-term use of supplemental vitamins and minerals does not reduce the risk of urothelial cell carcinoma of the bladder in the VITamins And Lifestyle study. 2011 , 185, 1210-5		39
339	G3T1 Bladder Cancer: Is Early Re-Resection Necessary?. 2011 , 4, 13-17		3
338	The enlightenment of bladder cancer treatment: origin and progress of photodynamic diagnosis. <i>Future Oncology</i> , 2011 , 7, 1057-66	3.6	1
337	Lectin mediated biorecognition as a novel strategy for targeted delivery to bladder cancer. 2011 , 186, 1481-8		24
336	BTA Stat: A Useful or an Unnecessary Urinary Marker in the Diagnosis of Primary Bladder Cancer?. 2011 , 5, 79-82		1
335	Cost-effectiveness of open versus laparoscopic versus robotic-assisted laparoscopic cystectomy and urinary diversion. 2011 , 21, 415-9		26
334	A healthy bladder: a consensus statement. 2011 , 65, 1026-36		80

333	Current and future clinical applications for optical imaging of cancer: from intraoperative surgical guidance to cancer screening. 2011 , 38, 109-18		74
332	External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2011 , 29, 409-14	4	45
331	Impact of gender on bladder cancer incidence, staging, and prognosis. <i>World Journal of Urology</i> , 2011 , 29, 457-63	4	154
330	Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. 2011 , 224, 270-9		62
329	Virtual bladder tumor transurethral resection: an objective evaluation tool to overcome learning curves with and without photodynamic diagnostics. 2011 , 87, 138-42		19
328	European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. 2011 , 20, 4268-81		105
327	Business models and opportunities for cancer vaccine developers. 2012 , 8, 1431-8		4
326	Bladder wall motion compensation using a new information-theoretic measure. 2012 ,		2
325	Surveillance and treatment of non-muscle-invasive bladder cancer in the USA. 2012 , 2012, 421709		26
324	The role of the androgen receptor in the development and progression of bladder cancer. <i>Japanese Journal of Clinical Oncology</i> , 2012 , 42, 569-77	2.8	60
323	[Interest of flexible videocystoscopy in blue light (+Hexvix(®)) in consultation for the diagnosis of vesical tumor]. 2012 , 22, 172-7		3
322	Multidetector computed tomography virtual cystoscopy: an effective diagnostic tool in patients with hematuria. 2012 , 79, 270-6		7
321	Lectin bioconjugates trigger urothelial cytoinvasion--a glycotargeted approach for improved intravesical drug delivery. 2012 , 82, 367-75		20
320	Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases. 2012 , 188, 2114-9		26
319	[Transurethral en bloc resection of non-muscle invasive bladder cancer. What is the state of the art?]. 2012 , 51, 798-804		2
318	Cost analysis of open radical cystectomy versus robot-assisted radical cystectomy. 2013 , 14, 26-31		33
317	Molecular targets on the horizon for kidney and urothelial cancer. 2013 , 10, 557-70		18
316	Office-based management of nonmuscle invasive bladder cancer. 2013 , 40, 473-9		4

315 Résumé du congrès de l'EAU 2013. **2013**, 23, F61-F64

- 314 Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. **2013**, 64, 624-38 156
- 313 Bladder cancer discussed on the internet: a systematic analysis of gender differences of initial posters on an online discussion board. **2013**, 2, 445 2
- 312 Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer. **2013**, 63, 145-54 56
- 311 Epidemiology and risk factors of urothelial bladder cancer. **2013**, 63, 234-41 1180
- 310 Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior. **2013**, 15, 749-60 21
- 309 Long-term NSAID use and incident urothelial cell carcinoma in the VITamins and Lifestyle (VITAL) study. *Urologic Oncology: Seminars and Original Investigations*, **2013**, 31, 1689-95 2.8 10
- 308 Disease specific mortality in patients with low risk bladder cancer and the impact of cystoscopic surveillance. **2013**, 189, 828-33 34
- 307 Cost-effectiveness of fluorescence in situ hybridization in patients with atypical cytology for the detection of urothelial carcinoma. **2013**, 190, 1181-6 27
- 306 Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarker. **2013**, 49, 2214-22 32
- 305 Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours. **2013**, 7, 719-31 64
- 304 Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer. **2013**, 13, 17 32
- 303 Motion correction for MR cystography by an image processing approach. **2013**, 60, 2401-10 8
- 302 Is photodynamic diagnosis ready for introduction in urological clinical practice?. **2013**, 13, 669-80 5
- 301 Total intracorporeal robotic cystectomy: are we there yet?. **2013**, 23, 135-40 23
- 300 Bladder wall thickness mapping for magnetic resonance cystography. **2013**, 58, 5173-92 7
- 299 Fluorescence image-guided photodynamic therapy of cancer cells using a scanning fiber endoscope. **2013**, 3 3
- 298 Expert review: an update in current and developing intravesical therapies for non-muscle-invasive bladder cancer. **2013**, 13, 1257-68 3

297	Bladder carcinoma in situ (CIS) in Australia: a rising incidence for an under-reported malignancy. 2013 , 112 Suppl 2, 46-52		2
296	Tumorträger möglichst früh identifizieren. 2013 , 17, 57-65		
295	The Changing Incidence of Carcinoma In-Situ of the Bladder Worldwide. 2013 ,		
294	What about conventional laparoscopic radical cystectomy? Cost-analysis of open versus laparoscopic radical cystectomy. <i>Journal of Endourology</i> , 2014 , 28, 410-5	2.7	8
293	The promise of novel molecular markers in bladder cancer. 2014 , 15, 23897-908		25
292	Bladder Cancer in Males: A Comprehensive Review of Urothelial Carcinoma of the Bladder. 2014 , 11, 18-27		3
291	Risk estimation of multiple recurrence and progression of non-muscle invasive bladder carcinoma using new mathematical models. 2014 , 38, 647-654		
290	Risk estimation of multiple recurrence and progression of non muscle invasive bladder carcinoma using new mathematical models. 2014 , 38, 647-54		3
289	Folate intake and risk of bladder cancer: a meta-analysis of epidemiological studies. 2014 , 65, 286-92		31
288	The burden of bladder cancer care: direct and indirect costs. 2014 , 24, 487-91		95
287	New imaging techniques for nonmuscle invasive bladder cancer. 2014 , 24, 532-9		8
286	Blue-light cystoscopy in the evaluation of non-muscle-invasive bladder cancer. 2014 , 6, 25-33		18
285	Smoking and smoking cessation effects on oncological outcomes in nonmuscle invasive bladder cancer. 2014 , 24, 492-9		25
284	Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States. 2014 , 66, 569-76		175
283	Comet assay measures of DNA damage are predictive of bladder cancer cell treatment sensitivity in vitro and outcome in vivo. 2014 , 134, 1102-11		20
282	Non-Muscle-Invasive Bladder Cancer in the Elderly Patient. 2014 , 3, 42-47		3
281	Biomimetic delivery strategies at the urothelium: targeted cytoinvasion in bladder cancer cells via lectin bioconjugates. 2014 , 31, 819-32		9
280	The economics of bladder cancer: costs and considerations of caring for this disease. 2014 , 66, 253-62		311

279	Urine markers for detection and surveillance of bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 222-9	2.8	77
278	Current evidence for transurethral en bloc resection of non-muscle-invasive bladder cancer. 2014 , 23, 206-13		26
277	The health economics of bladder cancer: an updated review of the published literature. 2014 , 32, 1093-104		118
276	Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors. 2014 , 26, 521-33		126
275	Time trends in municipal distribution patterns of cancer mortality in Spain. 2014 , 14, 535		39
274	Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer. 2014 , 18, 105-16		12
273	Vitamin A and risk of bladder cancer: a meta-analysis of epidemiological studies. 2014 , 12, 130		27
272	Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations. 2014 , 66, 863-71		57
271	Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. 2014 , 192, 708-13		50
270	Active surveillance for low-risk bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 33.e7-10	2.8	11
269	Intravesical bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer. 2015 ,		1
268	Economics of bladder cancer. 2015 , 90-102		
267	Human papilloma virus is not detectable in samples of urothelial bladder cancer in a central European population: a prospective translational study. 2015 , 10, 31		5
266	Biodistribution of Evans blue in an orthotopic AY-27 rat bladder urothelial cell carcinoma model: implication for the improved diagnosis of non-muscle-invasive bladder cancer (NMIBC) using dye-guided white-light cystoscopy. 2015 , 116, 468-77		6
265	Bladder reconstruction: The past, present and future. 2015 , 10, 3-10		31
264	Involvement of the Androgen and Glucocorticoid Receptors in Bladder Cancer. 2015 , 2015, 384860		19
263	High-dose chemotherapeutics of intravesical chemotherapy rapidly induce mitochondrial dysfunction in bladder cancer-derived spheroids. 2015 , 106, 69-77		26
262	Characterization of resection dexterity in transurethral resection of bladder tumor: A kinematic study. 2015 ,		3

261	Smoking and Bladder Cancer: A Systematic Review of Risk and Outcomes. 2015 , 1, 17-27		57
260	[Cost-effectiveness of transurethral resection of the bladder with blue light in patients with non muscle invasive bladder cancer in France]. 2015 , 25, 256-64		6
259	Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel. 2015 , 67, 363-75		128
258	Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia. <i>World Journal of Urology</i> , 2015 , 33, 1411-7	4	10
257	A novel excitation-emission wavelength model to facilitate the diagnosis of urinary bladder diseases. 2015 ,		2
256	Nanotechnology in bladder cancer: current state of development and clinical practice. 2015 , 10, 1189-201		28
255	Novel biomarkers to predict response and prognosis in localized bladder cancer. 2015 , 42, 225-33, ix		8
254	Surgical advances in bladder cancer: at what cost?. 2015 , 42, 235-52, ix		23
253	En bloc resection of urothelium carcinoma of the bladder (EBRUC): a European multicenter study to compare safety, efficacy, and outcome of laser and electrical en bloc transurethral resection of bladder tumor. <i>World Journal of Urology</i> , 2015 , 33, 1937-43	4	87
252	Reducing recurrence in non-muscle-invasive bladder cancer using photodynamic diagnosis and immediate post-transurethral resection of the bladder chemoprophylaxis. 2015 , 49, 230-6		14
251	Management of low-risk and intermediate-risk non-muscle-invasive bladder carcinoma. 2015 , 29, 219-25, vii		7
250	Detection of urinary bladder cancer cells using redox ratio and double excitation wavelengths autofluorescence. 2015 , 6, 977-86		23
249	[Role of blue-light cystoscopy in the management of non-muscle invasive bladder cancer]. 2015 , 25, 607-15		
248	Health-care services utilization and costs associated with radical cystectomy for bladder cancer: a descriptive population-based study in the province of Quebec, Canada. 2015 , 15, 308		9
247	Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study. 2015 , 194, 1202-8		35
246	Evaluating Evidence for Association of Human Bladder Cancer with Drinking-Water Chlorination Disinfection By-Products. 2015 , 18, 213-41		73
245	Bladder biopsy of normal-appearing mucosa is not helpful in patients with unexplained positive cytology after nonmuscle invasive bladder cancer. 2015 , 193, 48-52		6
244	Aurora A Kinase as a diagnostic urinary marker for urothelial bladder cancer. <i>World Journal of Urology</i> , 2015 , 33, 105-10	4	34

243	Combined cytotoxic effect of UV-irradiation and TiO ₂ microbeads in normal urothelial cells, low-grade and high-grade urothelial cancer cells. 2015 , 14, 583-90		20
242	Bladder cancer biomarker array to detect aberrant levels of proteins in urine. 2015 , 140, 724-35		22
241	Novel endoscopic diagnosis for bladder cancer. 2015 , 121, 169-78		45
240	The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Guérin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population. 2015 , 116, 753-63		39
239	Current evidence of transurethral Ho:YAG and Tm:YAG treatment of bladder cancer: update 2014. <i>World Journal of Urology</i> , 2015 , 33, 571-9	4	35
238	Review of current optical diagnostic techniques for non-muscle-invasive bladder cancer. 2016 , 69, 150-6		14
237	Research and Science Today 1(11)/2016. 2016 ,		
236	Multiplatform Biomarker Discovery for Bladder Cancer Recurrence Diagnosis. 2016 , 2016, 4591910		8
235	Capsaicin Suppresses Cell Proliferation, Induces Cell Cycle Arrest and ROS Production in Bladder Cancer Cells through FOXO3a-Mediated Pathways. 2016 , 21,		28
234	Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models. 2016 , 16, 351		7
233	Association between selected dietary scores and the risk of urothelial cell carcinoma: A prospective cohort study. 2016 , 139, 1251-60		40
232	Exploring glass as a novel method for hands-free data entry in flexible cystoscopy. 2016 ,		3
231	Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers. 2016 , 17, 15		8
230	Changes in autofluorescence based organoid model of muscle invasive urinary bladder cancer. 2016 , 7, 1193-200		11
229	Tailoring Soft Nanoparticles for Potential Application as Drug Carriers in Bladder Cancer Chemotherapy. 2016 , 167-195		1
228	4-HPR impairs bladder cancer cell migration and invasion by interfering with the Wnt5a/JNK and Wnt5a/MMP-2 signaling pathways. 2016 , 12, 1833-1839		5
227	What factors are associated with unplanned return following transurethral resection of bladder tumor? An analysis of a large single institution's experience. 2016 , 50, 370-3		10
226	Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden. 2016 , 117, E102-13		5

225	Improving early diagnosis of symptomatic cancer. 2016 , 13, 740-749		63
224	Predictors of costs associated with radical cystectomy for bladder cancer: A population-based retrospective cohort study in the province of Quebec, Canada. 2016 , 113, 223-8		6
223	Methodologies for bladder cancer detection with Raman based urine cytology. 2016 , 8, 4991-5000		19
222	Low awareness of risk factors among bladder cancer survivors: New evidence and a literature overview. 2016 , 60, 136-45		19
221	Hexaminolevulinate hydrochloride blue-light flexible cystoscopy in the detection and follow-up of nonmuscle-invasive bladder cancer: cost consequences during outpatient surveillance in Sweden. <i>Future Oncology</i> , 2016 , 12, 1025-38	3.6	7
220	Future directions in bladder cancer immunotherapy: towards adaptive immunity. 2016 , 8, 351-65		13
219	Critical Analysis of Hospital Readmission and Cost Burden After Robot-Assisted Radical Cystectomy. <i>Journal of Endourology</i> , 2016 , 30, 83-91	2.7	16
218	Computational model of bladder tissue based on its measured optical properties. 2016 , 21, 25006		16
217	High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ~240-Fold Higher Drug Concentration in Urine than Serum. 2016 , 15, 430-8		12
216	Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer. 2016 , 43, 47-62		58
215	Evaluation of Su Fu'ning Lotion's Inhibitory Effects on Bladder Cancer Cells In Vitro and In Vivo by Intravesical Instillation. 2016 , 15, 80-6		2
214	Current Evidence of Transurethral En-bloc Resection of Nonmuscle Invasive Bladder Cancer. 2017 , 3, 567-576		72
213	Urothelial Tumors and Dual-Band Imaging: A New Concept in Confocal Laser Endomicroscopy. <i>Journal of Endourology</i> , 2017 , 31, 538-544	2.7	10
212	Biomarker, Molecular, and Technologic Advances in Urologic Pathology, Oncology, and Imaging. 2017 , 141, 499-516		1
211	Microfluidic electrochemical multiplex detection of bladder cancer DNA markers. 2017 , 251, 34-39		28
210	Holmium YAG Photocoagulation: Safe and Economical Alternative to Transurethral Resection in Small Nonmuscle-Invasive Bladder Tumors. <i>Journal of Endourology</i> , 2017 , 31, 674-678	2.7	11
209	Urinary long noncoding RNAs in nonmuscle-invasive bladder cancer: new architects in cancer prognostic biomarkers. 2017 , 184, 108-117		41
208	Thymol inhibits bladder cancer cell proliferation via inducing cell cycle arrest and apoptosis. 2017 , 491, 530-536		34

207	Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 531.e15-531.e22	2.8	71
206	Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. 2017 , 197, 1419-1426		66
205	Virtual cystoscopy, computed tomography urography and optical cystoscopy for the detection and follow-up for bladder cancer. 2017 , 59, 422-430		2
204	Exploring exposure to Agent Orange and increased mortality due to bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 627-632	2.8	2
203	Advances in intravesical drug delivery systems to treat bladder cancer. 2017 , 532, 105-117		37
202	Virtual cystoscopy, computed tomography urography and optical cystoscopy for the detection and follow-up for bladder cancer. 2017 , 59, 422-430		1
201	Kinematic and experimental investigation of manual resection tools for transurethral bladder tumor resection. 2017 , 13, e1757		3
200	Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer. 2017 , 13, 783-791		16
199	A Pilot Study of Vela Laser for En Bloc Resection of Papillary Bladder Cancer. 2017 , 15, e311-e314		8
198	Bladder-Preserving Strategies in the Treatment of Urothelial Cancer. 2017 , 169-174		
197	. 2017 ,		
196	Androgen Receptor Signaling in Bladder Cancer. 2017 , 9,		45
195	Microdevices for Non-Invasive Detection of Bladder Cancer. 2017 , 5, 30		7
194	Contemporary cost-consequence analysis of blue light cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer. 2017 , 11, 173-181		6
193	Cost effectiveness and robot-assisted urologic surgery: does it make dollars and sense?. 2017 , 69, 313-323		17
192	Clinical interval and diagnostic characteristics in a cohort of bladder cancer patients in Spain: a multicenter observational study. 2017 , 10, 708		0
191	Expression and clinical significance of androgen receptor in bladder cancer: A meta-analysis. 2017 , 7, 919-927		9
190	Risk factor assessment in high-risk, bacillus Calmette-Guérin-treated, non-muscle-invasive bladder cancer. 2017 , 9, 195-202		9

189	Opportunities of next-generation sequencing in non-muscle invasive bladder cancer outcome prediction. 2017 , 6, 1043-1048		12
188	The contemporary role and impact of urine-based biomarkers in bladder cancer. 2017 , 6, 1031-1042		19
187	Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. 2018 , 73, 925-933		114
186	The Economic Burden of Bladder Cancer Due to Occupational Exposure. 2018 , 60, 217-225		5
185	Preliminary Porcine In Vivo Evaluation of a Telerobotic System for Transurethral Bladder Tumor Resection and Surveillance. <i>Journal of Endourology</i> , 2018 , 32, 516-522	2.7	10
184	The prognostic value of basal DNA damage level in peripheral blood lymphocytes of patients affected by bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 241.e15-241.e23	2.8	5
183	Clinical Utility of Cxbladder Monitor for Patients with a History of Urothelial Carcinoma: A Physician-Patient Real-World Clinical Data Analysis. 2018 , 6, 73-85		4
182	Role of the androgen receptor in urothelial cancer. 2018 , 465, 73-81		29
181	High Grade T1 Papillary Urothelial Bladder Cancer Shows Prominent Peritumoral Retraction Clefting. 2018 , 24, 567-574		3
180	Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients. 2018 , 73, 226-232		67
179	Associations of specific postoperative complications with costs after radical cystectomy. 2018 , 121, 428-436		23
178	Clinical Proteomics for Precision Medicine: The Bladder Cancer Case. 2018 , 12, 1700074		18
177	Monitoring the response of urothelial precancerous lesions to Bacillus Calmette-Guerin at the proteome level in an in vivo rat model. 2018 , 67, 67-77		3
176	The Rho GTPase signalling pathway in urothelial carcinoma. 2018 , 15, 83-91		9
175	Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer. 2018 , 142, 1797-1804		10
174	Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue. <i>International Journal of Hyperthermia</i> , 2018 , 34, 988-993	3.7	9
173	Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients: A systematic review and meta-analysis. 2018 , 97, e11596		24
172	Magnetic Sensing System for Monitoring the Volume of an Artificial Bladder. 2018 ,		3

171	Estrogen receptor β promotes bladder cancer growth and invasion via alteration of miR-92a/DAB2IP signals. 2018 , 50, 1-11		18
170	Cost comparison of laparoscopic versus robot-assisted radical cystectomy. 2018 , 7, 420-426		0
169	Immediate intravesical chemotherapy for low-grade bladder tumors in California: An underutilized practice and its impact on recurrence. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 498.e1-498.e7	2.8	1
168	Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC). 2018 , 35, 2054-2068		3
167	Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy. 2018 , 59, 98-105		20
166	An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2018 , 36, 1981-1995	4	52
165	Cruciferous Vegetables, Isothiocyanates, and Bladder Cancer Prevention. 2018 , 62, e1800079		66
164	Can tumor recurrence be reduced with plasma-kinetic vaporization of the area around the tumor in nonmuscle invasive bladder cancer?. 2018 , 59, 223-231		2
163	Promoter methylation of DNA damage repair (DDR) genes in human tumor entities: / is almost exclusively methylated in bladder cancer. 2018 , 10, 15		20
162	Finasteride does not prevent bladder cancer: A secondary analysis of the Medical Therapy for Prostatic Symptoms Study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 338.e13-338.e17	2.8	5
161	Enhanced Endoscopy in Bladder Cancer. 2018 , 19, 84		8
160	The knockdown of the Mediator complex subunit MED15 restrains urothelial bladder cancer cells' malignancy. 2018 , 16, 3013-3021		3
159	Who should record surgical complications? Results from a third-party assessment of complications after radical cystectomy. 2019 , 53, 339-343		1
158	Prognostic value and reproducibility of different microscopic characteristics in the WHO grading systems for pTa and pT1 urinary bladder urothelial carcinomas. 2019 , 14, 90		5
157	Predictive biomarkers for drug response in bladder cancer. 2019 , 26, 1044-1053		28
156	Usefulness of droplet digital PCR and Sanger sequencing for detection of FGFR3 mutation in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 907-915	2.8	4
155	TURBot: A System for Robot-Assisted Transurethral Bladder Tumor Resection. 2019 , 24, 1452-1463		11
154	N-Glycoproteomic Profiling Reveals Alteration In Extracellular Matrix Organization In Non-Type Bladder Carcinoma. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	10

153	Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer. 2019 , 127, 465-469		21
152	Correlation of BRCA2 gene mutation and prognosis as well as variant genes in invasive urothelial carcinoma of the bladder. 2019 , 25, 203-212		7
151	High Apelin Level Indicates a Poor Prognostic Factor in Muscle-Invasive Bladder Cancer. 2019 , 2019, 4586405		6
150	CARLo-7-A plausible biomarker for bladder cancer. 2019 , 100, 25-31		7
149	Chlorophyllin α 6-mediated photodynamic therapy inhibits proliferation and induces apoptosis in human bladder cancer cells. 2019 , 41, 2181-2193		11
148	Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection. <i>World Journal of Urology</i> , 2019 , 37, 2699-2705	4	10
147	Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma. 2019 , 22, 662-670		11
146	Selection of patients and benefit of immediate radical cystectomy for non-muscle invasive bladder cancer. 2019 , 8, 101-107		5
145	[Is a routine second transurethral resection of the bladder still necessary after hexaminol α ulinate photodynamic diagnosis-assisted TURBT?]. 2019 , 29, 332-339		1
144	The UroLife study: protocol for a Dutch prospective cohort on lifestyle habits in relation to non-muscle-invasive bladder cancer prognosis and health-related quality of life. 2019 , 9, e030396		1
143	Application of nomograms in the prediction of overall survival and cancer-specific survival in patients with T1 high-grade bladder cancer. 2019 , 18, 3405-3414		7
142	Cost comparison between open radical cystectomy, laparoscopic radical cystectomy, and robot-assisted radical cystectomy for patients with bladder cancer: a systematic review of segmental costs. 2019 , 19, 110		8
141	En-bloc resection versus conventional transurethral resection for patients with non-muscle-invasive bladder cancer. 2019 ,		78
140	Definitive BCG immunotherapy versus radical cystectomy in intermediate or high-risk nonmuscle invasive bladder cancer patients: A retrospective study. 2019 , 98, e16873		
139	Mental health implications in bladder cancer patients: A review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 97-107	2.8	27
138	Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. <i>World Journal of Urology</i> , 2019 , 37, 2059-2065	4	19
137	Circulating concentrations of B group vitamins and urothelial cell carcinoma. 2019 , 144, 1909-1917		6
136	A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera. 2020 , 146, 449-460		7

135	Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. 2020 , 39, 6265-6285		18
134	Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer. 2020 , 1, CD011935		9
133	Is the En Bloc Transurethral Resection More Effective than Conventional Transurethral Resection for Non-Muscle-Invasive Bladder Cancer? A Systematic Review and Meta-Analysis. 2020 , 104, 402-409		13
132	Fluid intake and clinicopathological characteristics of bladder cancer: the West Midlands Bladder Cancer Prognosis Programme. 2020 , 29, 110-118		
131	The Cost to Medicare of Bladder Cancer Care. 2020 , 3, 515-522		24
130	Apaziquone for Nonmuscle Invasive Bladder Cancer: Where Are We Now?. 2020 , 47, 73-82		3
129	Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers. 2020 , 13, 273-282		3
128	Urothelial Carcinoma Detection Based on Copy Number Profiles of Urinary Cell-Free DNA by Shallow Whole-Genome Sequencing. 2020 , 66, 188-198		15
127	Longitudinal patterns of cost and utilization of medicare beneficiaries with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 39.e11-39.e19	2.8	0
126	The grasper-integrated disposable flexible cystoscope is comparable to the reusable, flexible cystoscope for the detection of bladder cancer. 2020 , 10, 13495		2
125	Association of human papilloma virus (HPV) infection with oncological outcomes in urothelial bladder cancer. 2020 , 15, 52		8
124	Gender discrepancies in bladder cancer: potential explanations. 2020 , 20, 841-849		5
123	Histone Demethylase KDM7A Regulates Androgen Receptor Activity, and Its Chemical Inhibitor TC-E 5002 Overcomes Cisplatin-Resistance in Bladder Cancer Cells. 2020 , 21,		6
122	Deciding When to Omit Repeat Transurethral Resection of Superficial Bladder Cancer: Do Photodynamic Diagnostics help?. <i>Bladder Cancer</i> , 2020 , 6, 489-496		1
121	Bladder Cancer Incidence and Survival in the United States and Texas Non-Latino Whites and Latinos. <i>Bladder Cancer</i> , 2020 , 6, 497-506		1
120	Thrombomodulin Expression in Bladder Cancer Tissue and Its Association with Prognosis and Patient Survival. 2020 , 12, 157-165		1
119	Urinary MicroRNAs as Potential Markers for Non-Invasive Diagnosis of Bladder Cancer. 2020 , 21,		8
118	Mitotic activity index and CD25+ lymphocytes predict risk of stage progression in non-muscle invasive bladder cancer. 2020 , 15, e0233676		1

117	Advanced multimodal laser imaging tool for urothelial carcinoma diagnosis (AMPLITUDE). 2020 , 2, 021001	0	
116	Combined lectin- and immuno-histochemistry (CLIH) for applications in cell biology and cancer diagnosis: Analysis of human urothelial carcinomas. 2020 , 64,	4	
115	MRI of Bladder Cancer: Local and Nodal Staging. 2020 , 52, 649-667	20	
114	Risk for intravesical recurrence of bladder cancer stratified by the results on two consecutive UroVysion fluorescence in situ hybridization tests: a prospective follow-up study in Japan. 2020 , 25, 1163-1169 ⁸	8	
113	A Specific Blood Signature Reveals Higher Levels of S100A12: A Potential Bladder Cancer Diagnostic Biomarker Along With Urinary Engrailed-2 Protein Detection. 2019 , 9, 1484	3	
112	Cancer cell detection device for the diagnosis of bladder cancer from urine. 2021 , 171, 112699	7	
111	A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer. 2021 , 18, 308-317	1	
110	Androgen Suppression Therapy Is Associated with Lower Recurrence of Non-muscle-invasive Bladder Cancer. 2021 , 7, 142-147	6	
109	Automatic Diagnostic Tool for Predicting Cancer Grade in Bladder Cancer Patients Using Deep Learning. 2021 , 9, 115813-115825	2	
108	Sulforaphane Inhibits ICAM-1 Expression and Monocyte Adhesion in Human Bladder Cancer T24 Cells. 2021 , 34, 21		
107	Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB. <i>World Journal of Urology</i> , 2021 , 39, 2953-2960	4	1
106	Increasing costs from bladder cancer in the Brazilian Health System: the role of establishing public health policies. 2021 , 47, 443-447		3
105	The use of an automated electronic registry for bladder cancer surveillance during the SARS-CoV-2 pandemic. 205141582110001		1
104	Pembrolizumab for Non-Muscle-Invasive Bladder Cancer-A Costly Therapy in Search of Evidence. 2021 , 7, 501-502		2
103	Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text. 2021 , 15, E424-E460		1
102	Advances in Multiplexed Paper-Based Analytical Devices for Cancer Diagnosis: A Review of Technological Developments. 2021 , 6, 2001138		1
101	Subtype-associated epigenomic landscape and 3D genome structure in bladder cancer. 2021 , 22, 105		8
100	Perspective: Humanized Pig Models of Bladder Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021 , 8, 681044.6		1

99	Fluorinated Chitosan Mediated Synthesis of Copper Selenide Nanoparticles with Enhanced Penetration for Second Near-Infrared Photothermal Therapy of Bladder Cancer. 2021 , 4, 2100043	2
98	Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex. 2021 , 12, 3427	5
97	Implications of targeted next-generation sequencing for bladder cancer: report of four cases. 2021 , 19, 91	
96	Detrimental Effect of Various Preparations of the Human Amniotic Membrane Homogenate on the 2D and 3D Bladder Cancer Models. 2021 , 9, 690358	2
95	Plasmonic gold nanostars for synergistic photoimmunotherapy to treat cancer. 2021 , 10, 3295-3302	3
94	Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study. 2021 , 18, e1003732	5
93	Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review and Lesion-Level Diagnostic Meta-Analysis. 2021 , 13,	3
92	EMP2 induces cytostasis and apoptosis via the TGF β /SMAD/SP1 axis and recruitment of P2RX7 in urinary bladder urothelial carcinoma. 2021 , 44, 1133-1150	1
91	Folate Intake and Risk of Urothelial Carcinoma: A Systematic Review and Meta-Analysis of Epidemiological Studies. 2021 , 1-13	
90	Adjuvant chemotherapy in patients with locally advanced bladder cancer after neoadjuvant chemotherapy and radical cystectomy: a systematic review and pooled analysis. 2021 , 10, 283-291	1
89	[Treatment of Ta and T1 intermediate or high risk bladder cancer with intravesical Bacillus Calmette-Guérin or mitomycin C]. 2021 , 60, 234-237	0
88	Harnessing the Host Immune Response to Infection [BCG Immunotherapy for Bladder Cancer. 2015 , 387-403	1
87	Measuring priority symptoms in advanced bladder cancer: development and initial validation of a brief symptom index. 2013 , 11, 86-93	4
86	Benzalkonium bromide as a new potential instillation drug for bladder cancer: hypothesis and pilot study. 2011 , 17, HY36-9	6
85	A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer. 2017 , 12, e0170819	44
84	Role of androgen receptor expression in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. 2020 , 35, 423-432	5
83	Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo. 2014 , 5, 7917-35	50
82	Notch3 overexpression enhances progression and chemoresistance of urothelial carcinoma. 2017 , 8, 34362-34373	23

81	Mutation of the co-chaperone Tsc1 in bladder cancer diminishes Hsp90 acetylation and reduces drug sensitivity and selectivity. 2019 , 10, 5824-5834	6
80	Androgen deprivation therapy prevents bladder cancer recurrence. 2014 , 5, 12665-74	79
79	Honokiol inhibits bladder tumor growth by suppressing EZH2/miR-143 axis. 2015 , 6, 37335-48	41
78	Urine gamma-synuclein as a biomarker for the diagnosis of bladder cancer. 2016 , 7, 43432-43441	13
77	Intravesical immunotherapy in nonmuscle invasive bladder cancer. 2015 , 31, 304-11	6
76	Treatment options in non-muscle-invasive bladder cancer after BCG failure. 2015 , 31, 312-9	13
75	Synergistic Antitumor Activity of Vitamins C and K3 on Human Bladder Cancer Cell Lines. 2013 , 04, 7-19	7
74	Applicability of the EORTC risk tables to predict outcomes in non-muscle-invasive bladder cancer in Turkish patients. 2017 , 43, 48-54	6
73	Relationship between immunohistochemical staining extent of CD47 and histopathologic features of bladder tumor. 2017 , 70, 349-355	2
72	Currently Available Urine-Based Tumour Markers in the Detection of New and Recurrent Urothelial Bladder Cancer. 2011 , 4, 345-349	2
71	Epidemiology, Incidence and Mortality of Bladder Cancer and their Relationship with the Development Index in the World. 2016 , 17, 381-6	83
70	Diabetes Mellitus and Obesity as Risk Factors for Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis. 2021 , 12, 699732	4
69	Long-term outcomes of outpatient laser ablation for recurrent non-muscle invasive bladder cancer: A retrospective cohort study.. 2022 , 3, 124-129	1
68	Bladder Cancer Diagnosis and Detection: Current Status. 2011 , 63-77	
67	Advances in cystoscopic surveillance of superficial bladder cancer: detection of the invisible tumor. 2013 , 1, 6	1
66	Improved Diagnostic Techniques. 2015 , 155-170	
65	Non-muscle invasive bladder cancer: Are epicrises the 'Bermuda Triangle' of information transfer?. 2017 , 70, 245-251	2
64	A novel quinazoline derivative, MJ-56, exhibits phototoxicity toward human bladder cancer cells. 2018 ,	2

- 63 New Optical Improvements in Bladder Cancer Diagnosis: Seeing Better for a Better Management?. **2018**, 11-17
- 62 Ambulatory Bladder Cancer Care in the United States. **2019**, 6, 165-173
- 61 Lessons from Hands-Free Data Entry in Flexible Cystoscopy with Glass for Future Smart Assistance. **2020**, 63-87
- 60 Approaches for Personalized Drug Development in Bladder Cancer Patients. **2020**, 18, 91-98
- 59 Evaluation of androgen receptor status in urothelial carcinoma of the urinary bladder in Egyptian patients: an immunohistochemical study. **2020**, 26,
- 58 Postoperative Recurrent Bladder Tumors Detection by Narrow-Band Imaging Cystoscopy. **2020**, 18, 209-214 ○
- 57 Cystoscopic Diagnosis of Bladder Cancer Using Artificial Intelligence. **2021**, 42,
- 56 Investigation of Bladder Cancer Cell Response to Cryoablation and Adjunctive Cisplatin Based Cryo/Chemotherapy.. **2020**, 6, 2
- 55 Subtype-specific epigenomic landscape and 3D genome structure in bladder cancer. 2
- 54 Gender Differences in Urothelial Bladder Cancer: Effects of Natural Killer Lymphocyte Immunity. *Journal of Clinical Medicine*, **2021**, 10, 5.1 ○
- 53 Recurrence in Non-Muscle Invasive Bladder Cancer Patients: External Validation of the EORTC, CUETO and EAU Risk Tables and Towards a Non-Linear Survival Model. *Bladder Cancer*, **2020**, 6, 277-284 ¹
- 52 Evaluation of a Novel Cystoscopic Compatible Cryocatheter for the Treatment of Bladder Cancer. *Bladder Cancer*, **2020**, 6, 303-318 1 1
- 51 Risk factors for bladder cancer: challenges of conducting a literature search using PubMed. **2011**, 8, 1e 2
- 50 Vitamin C and E intake and risk of bladder cancer: a meta-analysis of observational studies. *International Journal of Clinical and Experimental Medicine*, **2014**, 7, 4154-64 12
- 49 Sweet-P inhibition of glucocorticoid receptor has a potential cancer therapy. *Journal of Plant Sciences (Science Publishing Group)*, **2016**, 3, 1.5 5
- 48 Analysis of bladder cancer tumor CpG methylation and gene expression within The Cancer Genome Atlas identifies as a prognostic biomarker for basal-like bladder cancer. *American Journal of Cancer Research*, **2017**, 7, 1850-1862 4.4 5
- 47 Epidemiology and Hospitalization Cost of Bladder Cancer in Kerman Province, Southeastern Iran. *Iranian Journal of Public Health*, **2018**, 47, 567-574 0.7
- 46 The Real-World Lifetime Economic Burden of Urothelial Carcinoma by Stage at Diagnosis. **2020**, 6, 51-60 2

45	Loco-regional deep hyperthermia combined with intravesical Mitomycin instillation reduces the recurrence of non-muscle invasive papillary bladder cancer. <i>International Journal of Hyperthermia</i> , 2021 , 38, 1627-1632	3.7	0
44	RNA-binding proteins RBM-HuR, RBM3 and PODXL expression in urothelial carcinoma of the urinary bladder. Prognostic and clinical implications.. <i>Wspolczesna Onkologia</i> , 2021 , 25, 279-290	1	
43	Artificial intelligence for segmentation of bladder tumor cystoscopic images performed by U-Net with dilated convolution.. <i>Journal of Endourology</i> , 2022 ,	2.7	2
42	Potential therapeutic effects of adjuvant chemotherapy after neoadjuvant chemotherapy for locally advanced muscle-invasive bladder cancer.. <i>Japanese Journal of Clinical Oncology</i> , 2022 ,	2.8	
41	Dietary B group vitamin intake and the bladder cancer risk: a pooled analysis of prospective cohort studies.. <i>European Journal of Nutrition</i> , 2022 , 1	5.2	0
40	An Unfolded Protein Response Related Signature Could Robustly Predict Survival Outcomes and Closely Correlate With Response to Immunotherapy and Chemotherapy in Bladder Cancer.. <i>Frontiers in Molecular Biosciences</i> , 2021 , 8, 780329	5.6	0
39	Chemoprevention of Urothelial Cell Carcinoma Tumorigenesis by Dietary Flavokawain A in UPII-Mutant Ha-ras Transgenic Mice.. <i>Pharmaceutics</i> , 2022 , 14,	6.4	2
38	Stage-Related Cost of Treatment of Bladder Cancer in Brazil.. <i>PharmacoEconomics - Open</i> , 2022 , 1	2.1	0
37	Effect of diabetes mellitus and glycemic control on the prognosis of invasive bladder cancer. <i>Pakistan Biomedical Journal</i> , 2021 , 5,		
36	Customized Multilayered Tissue-on-a-Chip (MToC) to Simulate Bacillus Calmette-Guérin (BCG) Immunotherapy for Bladder Cancer Treatment. <i>Biochip Journal</i> , 2022 , 16, 67-81	4	1
35	The effect of metformin on bladder cancer incidence and outcomes – a systematic review and meta-analysis. <i>Bladder Cancer</i> , 2022 , 1-18	1	0
34	The learning curve in bladder MRI using VI-RADS assessment score during an interactive dedicated training program.. <i>European Radiology</i> , 2022 , 1	8	0
33	Photodynamic methods of treatment of nonmuscular-invasive bladder cancer. <i>Urologicheskie Vedomosti</i> , 2021 , 11, 355-363	0.7	
32	Quality of life patterns and its association with predictors among non-muscle invasive bladder cancer survivors: A latent profile analysis. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2022 ,	2.2	
31	Diagnostic performance of minichromosome maintenance 5 (MCM5) in bladder cancer: A systematic review and meta-analysis.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022 ,	2.8	1
30	Data_Sheet_1.PDF. 2020 ,		
29	Table_1.XLSX. 2020 ,		
28	En bloc resection, is this the future of non-muscle invasive bladder cancer management? Presentation of our technique and brief review of the literature.. <i>Urologia</i> , 2022 , 3915603221093739	1.2	

27	En bloc resection of bladder tumors: challenges and unmet needs in 2022. <i>Future Oncology</i> , 2022 , 18, 2545-2558	3.6	1
26	Machine learning decision support model for radical cystectomy discharge planning. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022 ,	2.8	0
25	The natural history of low-risk non-muscle-invasive bladder cancer: a collaborative multi-centre study. <i>International Urology and Nephrology</i> ,	2.3	
24	Usefulness of the Urine Methylation Test (Bladder EpiCheck [®]) in Follow-Up Patients with Non-Muscle Invasive Bladder Cancer and Cytological Diagnosis of Atypical Urothelial Cells: An Institutional Study. <i>Journal of Clinical Medicine</i> , 2022 , 11, 3855	5.1	1
23	The use of blue-light cystoscopy in the detection and surveillance of nonmuscle invasive bladder cancer. Publish Ahead of Print,		
22	Photodynamic Therapy for Bladder Cancers, A Focused Review.		0
21	Biomarkers to assess the risk of bladder cancer in patients presenting with haematuria are gender-specific. 12,		0
20	Analysing cause of death during follow-up for non-muscle-invasive bladder cancer: is there a role for watchful waiting?.		0
19	New Mental Health Diagnosis as a Prognostic Factor for Muscle-Invasive Bladder Cancer. 2022 ,		0
18	IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.		1
17	Identification and validation of methylated PENK gene for early detection of bladder cancer using urine DNA. 2022 , 22,		0
16	Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups. 2022 , 23, 14481		0
15	Bladder EpiCheck urine test in the follow-up of NMIBC: a cost analysis.		0
14	Cost of bladder cancer in Lebanon before and after the economic collapse: A probabilistic modeling study.		0
13	Clinical and economic impact of blue light cystoscopy in the management of NMIBC at US ambulatory surgical centers: what is the site-of-service disparity?. 2022 ,		0
12	UROSCAN and UROSCANSEQ: a large-scale multicenter effort towards translation of molecular bladder cancer subtypes into clinical practice [from biobank to RNA-sequencing in real time. 1-8		0
11	Direct and indirect medical costs of bladder cancer in Iran. 2023 , 21,		0
10	Study protocol: transurethral REsection and Single instillation intravesical chemotherapy Evaluation in bladder Cancer Treatment (RESECT). A multi-centre international observational study with embedded cluster randomised trial of audit, feedback and education. (Preprint).		0

- 9 VI-RADS in bladder cancer: Overview, pearls and pitfalls. **2023**, 110666
- 8 Combination of hyperthermia and intravesical chemotherapy for the treatment of pT1 stage bladder cancer: A retrospectively clinical study.
- 7 Audit, feedback, and education to improve quality and outcomes in transurethral REsection and Single instillation intravesical chemotherapy for non-muscle invasive bladder Cancer Treatment (RESECT): Protocol for a multi-centre international observational study with embedded cluster randomised trial. (Preprint).
- 6 Long-term prevention of bladder cancer progression by alpha1-oleate alone or in combination with chemotherapy.
- 5 Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer. **2023**,
- 4 Noninvasive Detection of Bladder Cancer Markers Based on Gold Nanomushrooms and Sandwich Immunoassays. **2023**, 6, 5557-5567
- 3 Extracellular Vesicles as Potential Bladder Cancer Biomarkers: Take It or Leave It?. **2023**, 24, 6757
- 2 Microscopic hematuria and pelvic ultrasonography could rule out flexible cystoscopy during surveillance for T1-low grade non-muscle invasive bladder cancer. 1-6
- 1 Non-Invasive Imaging Modalities in Intravesical Murine Models of Bladder Cancer. **2023**, 15, 2381